Med7 LLC, announce the completion of a safety and efficacy study using Hempzorb81TM Full Spectrum Hemp Oil in patients with Type II Diabetes - il Centro Tirreno - Quotidiano online
Il sito "il Centro" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
Lun, Mag

Med7 LLC, announce the completion of a safety and efficacy study using Hempzorb81TM Full Spectrum Hemp Oil in patients with Type II Diabetes

  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

BLUFFDALE, Utah, May 4, 2021 /PRNewswire/ -- Med7, LLC ( and HempCo, Inc. announce the completion of a human clinical study in patients with Type II Diabetes using Purzorb® technology, now trademarked as Hempzorb81TM. "This study will provide our customers and providers with evidence based products not seen to this

point in the Industrial Hemp and CBD market place," said Matt Smith, CEO of Med7. This study was done with support from the National Institutes of Health (NIH) as part of their small business grant program.  

In this placebo-controlled study on 150 patients with Type II Diabetes, Hempzorb81TM demonstrated a significant effect on lowering the A1c with an average drop of 1.2 points versus placebo over six-months. Patients on Hempzorb81TM also lost an average of 14 lbs. and reduced their girth by 4 inches over placebo ( 

Cannabidiol (CBD) alone or in combination with other cannabinoids has never shown a proven clinical effect in glucose management in large placebo-controlled studies. "A naturally occurring whole plant extract with multiple cannabinoids and other natural components can have strong entourage effects on cannabinoid receptors if they can get into the blood stream effectively," according to Paul Murray, CEO of HempCo. "These studies should give consumers and providers confidence that there are hemp products containing CBD that are backed by human clinical studies."   

Med7 also received support from the NIH with two other studies: The effect of Hempzorb81TM in Sleep Cycles and in patients with COVID-19.  "The study in COVID-19 patients was serendipitous to our Diabetes study and the pandemic. In the first few months of this clinical trial, COVID-19 hit the study group hard," said Smith. "None of the study subjects with COVID-19 dropped out of the study or were hospitalized so we studied these patients more closely. We are evaluating these results and hope to release them soon."     

About Med7  

Med7® is a technology-driven health and wellness company that distributes full spectrum hemp CBD oil products using Purzorb® to medical professionals. Purzorb® is a patent pending technology that mimics the body's natural process of absorption by converting oil-based nutrients into water-soluble products.  

Logo -